Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

CytomX Therapeutics
650 Gateway Blvd., Suite 125
South San Francisco, CA 94080
Phone: 650-515-3185
www.cytomx.com

CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's novel Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics, and is based on a robust and growing intellectual property estate. This novel platform is driving the development of Probodies, which are masked antibodies that remain inert in healthy tissue but are activated by proteases within the disease microenvironment. This new level of tissue activation and selectivity enables CytomX to access new targets and expand the therapeutic index of existing targets.

Key Contact
Name
Sean McCarthy
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
07/31/12 $41,000,000 Series B Canaan Partners
Roche Venture Fund
undisclosed